New England Research & Management, Inc. Alnylam Pharmaceuticals, Inc. Transaction History
New England Research & Management, Inc.
- $204 Million
- Q1 2024
Shares
2 transactions
Others Institutions Holding ALNY
# of Institutions
585Shares Held
104MCall Options Held
2.82MPut Options Held
1.75M-
Capital World Investors Los Angeles, CA12.8MShares$3.21 Billion0.33% of portfolio
-
Vanguard Group Inc Valley Forge, PA12MShares$3.01 Billion0.04% of portfolio
-
Black Rock Inc. New York, NY9.03MShares$2.27 Billion0.03% of portfolio
-
Wellington Management Group LLP Boston, MA7.21MShares$1.81 Billion0.2% of portfolio
-
Baillie Gifford & CO6.62MShares$1.66 Billion0.78% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $30.9B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...